| CAS NO: | 159811-51-5 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| Molecular Weight (MW) | 433.58 |
|---|---|
| Formula | C28H35NO3 |
| CAS No. | 159811-51-5 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility(In vitro) | DMSO: 83 mg/mL (191.4 mM) |
| Water: <1 mg/mL | |
| Ethanol: 14 mg/mL (32.3 mM) | |
| Other info | Chemical Name: (8S,11R,13S,14S,17R)-17-acetyl-11-(4-(dimethylamino)phenyl)-13-methyl-3-oxo-2,3,6,7,8,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate InChi Key: OOLLAFOLCSJHRE-ZHAKMVSLSA-N InChi Code: InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1 SMILES Code: CC([C@@]1(OC(C)=O)CC[C@@]2([H])[C@]3([H])CCC4=CC(CCC4=C3[C@@H](C5=CC=C(N(C)C)C=C5)C[C@]12C)=O)=O |
| Synonyms | CDB-2914; HRP2000, VA2914, RTI 3021-012, RU 44675, CDB2914, HRP 2000, VA-2914, CDB 2914, CDB-2914, CDB 2914, CDB2914, HRP-2000, VA 2914, Ulipristal acetate, EllaOne, Ella, Esmya |
| In Vitro | In vitroactivity: Ulipristal acetate has partial agonistic as well as antagonistic effects on the progesterone receptor. It also binds to theglucocorticoid receptor, but has no relevant affinity to the estrogen, androgen and mineralocorticoid receptors. |
|---|---|
| In Vivo | Based on clinical trials, ulipristal acetate seems to be a reasonably tolerable and effective method of emergency contraception when used within 120 hours of intercourse. Ulipristal acetate is at least as effective as LNG when used within the first 72 hours after unprotected intercourse. However, ulipristal acetate may be more effective than LNG when used between 72 to 120 hours after unprotected intercourse, extending the window of opportunity for emergency contraception. |
| Animal model | |
| Formulation & Dosage | |
| References | J Steroid Biochem Mol Biol. 2004 Mar;88(3):277-88; Clin Ther. 2012 Jan;34(1):24-36. |
m.cnreagent.com
